Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 3/20 | 0.54 |
| ▸ | GSR | P00390 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.54 |
| ▸ | GRM8 | O00222 | 1/20 | 0.54 |
| ▸ | GRM6 | O15303 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.54 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28096046 | 0.84 | LMNA (0.46) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL4537585 | 0.84 | LMNA (0.46) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL2241803 | 0.84 | LMNA (0.46) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL24991839 | 0.83 | SLC1A1 (0.48) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL710038 | 0.82 | SLC1A1 (0.56) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL27939784 | 0.81 | GABRP (0.54) | SLC1A1ALOX15LMNAALDH1A1 | |
| SCHEMBL16523558 | 0.81 | LMNA (0.43) | SLC1A1LMNA | |
| Ammonia Solution, Strong SCHEMBL29126346 | 0.80 | SLC1A1 (0.54) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL404449 | 0.80 | SLC1A1 (0.54) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL29094232 | 0.80 | SLC1A1 (0.54) | SLC1A1GSRSLC1A3SLC1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117017830-A | Solubilizing composition and use thereof | 华熙生物科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-114478324-B | Active compound and application thereof in side chain carboxyl compound protection | 上海嘉莱多生物技术有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-114478324-A | Active compound and application thereof in side chain carboxyl compound protection | 上海嘉莱多生物技术有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-101365415-B | Gelling agent | AJINOMOTO KK | 2012-09-12 | — | — | CN | disclosed |
| US-8084499-B2 | Modified clay mineral | AJINOMOTO CO., INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| EP-2345733-A1 | PROCESS FOR PRODUCING N-PROTECTED AMINO ACID | Kaneka Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20090098169-A1 | MODIFIED CLAY MINERAL | AJINOMOTO CO., INC (JP) | 2009-04-16 | — | — | US | disclosed |
| CN-101365415-A | Gelling agent | AJINOMOTO KK (JP) | 2009-02-11 | — | — | CN | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0572167-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-10-09 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098169-A1 | MODIFIED CLAY MINERAL | CUTA, ARG1, AS3MT | SLC1A1 2292/4885GSR 551/4885SLC1A3 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.